Cipher Pharmaceuticals Inc. (CPH.TO)
- CNW Group
Cipher Pharmaceuticals Partner Moberg Pharma AB Provides Update on MOB-015 Phase 3 Study
Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") announced today that its partner, Moberg Pharma AB ("Moberg"), issued a news release earlier today stating that it has received information about clinical cure in a subset of patients in the ongoing North American Phase 3 study for MOB-015, a product for the treatment of nail fungus. Moberg has noted that the number of patients who have achieved clinical cure in this blinded subset of patients is lower than its exp
- Simply Wall St.
Undiscovered Gems In Canada To Watch This September 2024
Over the last 7 days, the Canadian market has remained flat, but it is up 13% over the past year with earnings forecasted to grow by 15% annually. In this context, identifying stocks with strong growth potential and solid fundamentals can be particularly rewarding for investors.
- Simply Wall St.
Three Undiscovered Gems In Canada To Enhance Your Portfolio
The Canadian market has recently seen a dramatic recovery, rebounding from an early August pullback of nearly 5%, driven by a resilient economy and broadening earnings growth. As the focus shifts towards growth amid easing monetary policies, now is an opportune time to explore lesser-known stocks that could offer substantial potential for your portfolio.
